HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

clebopride

antidopaminergic; RN given refers to parent cpd; structure
Also Known As:
N-1-benzyl-4 piperidil-3-methoxy-4-amino-5-chlorobenzamide; clebopride fumarate (1:1); clebopride maleate; clebopride maleate (1:1); clebopride mono-hydrochloride; cleboril; N-(1'-benzyl-4'-piperidyl)-2-methoxy-4-amino-5- chlorobenzamide
Networked: 41 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Jang, Tae Chang: 1 article (05/2019)
2. Kim, Gyun Moo: 1 article (05/2019)
3. Ko, Seung Hyun: 1 article (05/2019)
4. Seo, Young Woo: 1 article (05/2019)
5. Choi, Jin Kyo: 1 article (01/2017)
6. Hong, Jin Yong: 1 article (01/2017)
7. Allocca, R: 1 article (06/2012)
8. Amboni, M: 1 article (06/2012)
9. Barone, P: 1 article (06/2012)
10. Erro, R: 1 article (06/2012)

Related Diseases

1. Vomiting
2. Dyspepsia (Indigestion)
3. Nausea
4. Catalepsy
12/01/1996 - "Administration of the D1 antagonist SCH 23390 (0.2 or 1.0 mg/kg) or the D2 antagonist clebopride (1.0, 10.0, or 20.0 mg/kg) led to catalepsy and dorsal immobility in intact rats, regardless of test age. "
11/01/1995 - "However, combined administration of SCH 23390 + clebopride induced similar akinesia, catalepsy, and somatosensory neglect in both controls and DA depleted animals. "
11/07/1994 - "Moreover, since important changes in DA receptor ontogeny occur during the first postnatal week, we compared the ability of the D1-like antagonist, SCH 23390 (0.2 mg/kg), or the D2-like antagonists, clebopride (10.0 mg/kg) and haloperidol (1.0 mg/kg), to induce akinesia or catalepsy in adults depleted of DA on either day 1 or on day 3. Rats depleted of striatal DA (> 95%) at either age exhibited similar subsensitivity to D1 or D2 antagonists. "
11/01/1995 - "The ability of bilateral intrastriatal injections (0.5 microliter) of DA receptor antagonists to induce motoric deficits was determined in adult rats treated with vehicle or 6-OHDA (100 micrograms, intraventricular) on postnatal day 3. Administration of the D1-like antagonist SCH 23390 (0.5-2.0 micrograms) or the D2-like antagonist clebopride (1.0-4.0 micrograms) induced dose-dependent akinesia, catalepsy, and somatosensory neglect in vehicle-treated controls. "
06/11/1993 - "In the present study, we investigated the ability of NMDA receptor antagonists to inhibit catalepsy induced by haloperidol, or SCH23390 and clebopride, selective dopamine D1 and D2 receptor antagonists respectively. "
5. Gastritis

Related Drugs and Biologics

1. Cisapride (Propulsid)
2. Metoclopramide (Reglan)
3. Cisplatin (Platino)
4. Domperidone (Domperidon)
5. SCH 23390
6. Haloperidol (Haldol)
7. Antiemetics
8. N-Methyl-D-Aspartate Receptors (NMDA Receptors)
9. Dopamine (Intropin)
10. Dopamine Antagonists

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Therapeutics
3. Oral Administration
4. Gamma Cameras (Gamma Camera)
5. Injections